文献速递糖尿病

电化学发光法检测GAD65自身抗体结合临床表型提升成人自身免疫性糖尿病识别

Improving clinical utility of GAD65 autoantibodies by electrochemiluminescence assay and clinical phenotype when identifying autoimmune adult-onset diabetes.
PubMed 文献 · Diabetologia · 2021-07-16

研究基于Action LADA(n=6156)和DiYA(n=2063)两个队列,分析771例和2063例成年起病糖尿病患者,比较放射结合法(RBA)与电化学发光法(ECL)检测GAD65自身抗体(GADA)的临床效用。结果显示ECL-GADA阳性者更需早期胰岛素治疗、多胰岛自身抗体阳性且超重较少(均p<0.0001),临床表型、诊断年龄和BMI可独立提高胰岛素治疗需求的阳性预测值,RBA阳性但ECL未确认者表型更接近2型糖尿病。

要点

  • ECL法检测GADA较RBA法更能识别需早期胰岛素治疗的成人自身免疫糖尿病。
  • 临床表型、诊断年龄和BMI可独立提升胰岛素治疗需求的阳性预测值。
  • RBA-GADA阳性而ECL未确认者抗体亲和力较低,表型更接近2型糖尿病。

核心结论

  • ECL法检测GADA结合临床表型可更准确识别成人起病自身免疫糖尿病并指导管理。

研究设计与样本

  • 分析Action LADA研究(n=6156)中771例30-70岁糖尿病患者和DiYA研究中2063例20-45岁糖尿病患者。

主要发现

  • 两队列中GADA均为最常见自身抗体,占比>90%。
  • ECL-GADA阳性者更需早期胰岛素治疗、多胰岛自身抗体阳性且超重较少(均p<0.0001)。
  • 临床表型、诊断年龄和BMI独立提高胰岛素治疗需求的阳性预测值,甚至增强ECL-GADA的预测价值。
  • RBA-GADA阳性但ECL未确认者表型更接近2型糖尿病,且GADA亲和力较低。

临床怎么用

  • 采用ECL法检测GADA并结合临床表型(诊断年龄、BMI)评估成人糖尿病分型及胰岛素治疗需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: It is important to differentiate the two major phenotypes of adult-onset diabetes, autoimmune type 1 diabetes and non-autoimmune type 2 diabetes, especially as type 1 diabetes presents in adulthood. Serum GAD65 autoantibodies (GADA) are the most sensitive biomarker for adult-onset autoimmune type 1 diabetes, but the clinical value of GADA by current standard radiobinding assays (RBA) remains questionable. The present study focused on the clinical utility of GADA differentiated by a new electrochemiluminescence (ECL) assay in patients with adult-onset diabetes. METHODS: Two cohorts were analysed including 771 diabetic participants, 30-70 years old, from the Action LADA study (n = 6156), and 2063 diabetic participants, 20-45 years old, from the Diabetes in Young Adults (DiYA) study. Clinical characteristics of participants, including requirement of early insulin treatment, BMI and development of multiple islet autoantibodies, were analysed according to the status of RBA-GADA and ECL-GADA, respectively, and compared between these two assays. RESULTS: GADA was the most prevalent and predominant autoantibody, >90% in both cohorts. GADA positivity by either RBA or ECL assay significantly discriminated clinical type 1 from type 2 diabetes. However, in both cohorts, participants with ECL-GADA positivity were more likely to require early insulin treatment, have multiple islet autoantibodies, and be less overweight (for all p < 0.0001). However, clinical phenotype, age at diagnosis and BMI independently improved positive predictive value (PPV) for the requirement of insulin treatment, even augmenting ECL-GADA. Participants with GADA detectable by RBA, but not confirmed by ECL, had a phenotype more similar to type 2 diabetes. These RBA-GADA positive individuals had lower affinity GADA compared with participants in which GADA was confirmed by ECL assay. CONCLUSIONS/INTERPRETATION: Detection of GADA by ECL assay, given technical advantages over RBA-GADA, identified adult-onset diabetes patients at higher risk of requiring early insulin treatment, as did clinical phenotype, together allowing for more accurate clinical diagnosis and management.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Gu Y, Jia X, Vartak T, et al. Improving clinical utility of GAD65 autoantibodies by electrochemiluminescence assay and clinical phenotype when identifying autoimmune adult-onset diabetes. Diabetologia. 2021. PMID: 34272582. doi:10.1007/s00125-021-05492-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。